FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4298277459> ?p ?o ?g. }

• W4298277459 endingPage "32" @default.
• W4298277459 startingPage "29" @default.
• W4298277459 abstract "Nephrologists should promote the detection of CKD in heart disease patients. The evaluation should include estimation of GFR and detection of microalbuminuria in a recently voided urine sample by the albumin:creatinine ratio. Any patient with stage 3 or 4 CKD and rapid deterioration of GFR should be evaluated by the nephrologist. - Patients with CKD have a high risk of cardiovascular (CV) complications and heart disease patients have a high incidence of CKD and progression is also more rapid (Strength of Recommendation B). The most likely pathophysiological hypothesis is endothelial damage. - The CV risk profile should be established in each patient followed by adequate compliance with control goals for common CV risk factors: smoking, obesity, sedentarism, hypertension, dyslipidemia. Early treatment of anemia and bone mineral disease as CV risk factors requires special mention (Strength of Recommendation B). - Management of these patients will be based on individualization of treatment, close systematic follow-up, and integration between care levels: Specialized care (nephrologists and cardiologists) and primary care. - The cardiorenal syndrome (CRS) is a condition in which both organs are simultaneously affected and their deleterious effects are reinforced in a feedback cycle, with accelerated progression of renal and myocardial damage. Because of its prognostic value, treatment of HF takes precedence over CKD. Most studies on cardiovascular risk and on HF exclude patients with stage 4-5 CKD. We thus do not have sufficient strong evidence and recommendations are based on the extrapolation of data from studies with normal GFR or milder grades of CKD, and on the empirical use of certain treatments. - ARBs and ACEIs are the mainstays of treatment of HF with systolic and diastolic dysfunction, and have been shown to reduce mortality in studies in the general population (Strength of Recommendation A). The may also slow progression of CKD, especially in diabetics. Dual renin-angiotensin blockade with the combined use of lower doses of both drugs has shown promising results for control of CKD progression, but there are no data to recommend its use for control of HF in advanced stages of CKD (stage 4-5) (Strength of Recommendation C). - In these stages of CKD, only loop diuretics have sufficient potency. The therapeutic dose range should be achieved. Lowdose thiazides achieve diuretic synergy. The use of spironolactone and eplerenone has shown benefits in patients with AMI and HF with an ejection fraction < 40% without advanced CKD. They should always be used with strict control of GFR and K+. No benefit has been shown for the use of <<dopamine in diuretic doses>> (may even be harmful) or continuous infusion of furosemide (Strength of Recommendation B). The use of beta-blockers should be increased in these patients. - Treatment-refractory heart failure in the context of stage 3 CKD could be amenable to ultrafiltration techniques. Continuous ambulatory PD could be an alternative treatment to maintain hemodynamic equilibrium while also allowing pharmacological treatments to be prescribed that would not be feasible without dialysis and could even improve myocardial and kidney function (Strength of Recommendation C)." @default.
• W4298277459 created "2022-10-01" @default.
• W4298277459 creator A5012382618 @default.
• W4298277459 creator A5087425433 @default.
• W4298277459 date "2008-01-01" @default.
• W4298277459 modified "2023-10-17" @default.
• W4298277459 title "[Cardiorenal syndrome]." @default.
• W4298277459 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19018735" @default.
• W4298277459 hasPublicationYear "2008" @default.
• W4298277459 type Work @default.
• W4298277459 citedByCount "1" @default.
• W4298277459 countsByYear W42982774592023 @default.
• W4298277459 crossrefType "journal-article" @default.
• W4298277459 hasAuthorship W4298277459A5012382618 @default.
• W4298277459 hasAuthorship W4298277459A5087425433 @default.
• W4298277459 hasConcept C120665830 @default.
• W4298277459 hasConcept C121332964 @default.
• W4298277459 hasConcept C126322002 @default.
• W4298277459 hasConcept C134018914 @default.
• W4298277459 hasConcept C159641895 @default.
• W4298277459 hasConcept C164705383 @default.
• W4298277459 hasConcept C177713679 @default.
• W4298277459 hasConcept C2778096610 @default.
• W4298277459 hasConcept C2778198053 @default.
• W4298277459 hasConcept C2778653478 @default.
• W4298277459 hasConcept C2779134260 @default.
• W4298277459 hasConcept C2780578515 @default.
• W4298277459 hasConcept C2781203188 @default.
• W4298277459 hasConcept C2781309322 @default.
• W4298277459 hasConcept C511355011 @default.
• W4298277459 hasConcept C54847362 @default.
• W4298277459 hasConcept C555293320 @default.
• W4298277459 hasConcept C61511704 @default.
• W4298277459 hasConcept C71924100 @default.
• W4298277459 hasConceptScore W4298277459C120665830 @default.
• W4298277459 hasConceptScore W4298277459C121332964 @default.
• W4298277459 hasConceptScore W4298277459C126322002 @default.
• W4298277459 hasConceptScore W4298277459C134018914 @default.
• W4298277459 hasConceptScore W4298277459C159641895 @default.
• W4298277459 hasConceptScore W4298277459C164705383 @default.
• W4298277459 hasConceptScore W4298277459C177713679 @default.
• W4298277459 hasConceptScore W4298277459C2778096610 @default.
• W4298277459 hasConceptScore W4298277459C2778198053 @default.
• W4298277459 hasConceptScore W4298277459C2778653478 @default.
• W4298277459 hasConceptScore W4298277459C2779134260 @default.
• W4298277459 hasConceptScore W4298277459C2780578515 @default.
• W4298277459 hasConceptScore W4298277459C2781203188 @default.
• W4298277459 hasConceptScore W4298277459C2781309322 @default.
• W4298277459 hasConceptScore W4298277459C511355011 @default.
• W4298277459 hasConceptScore W4298277459C54847362 @default.
• W4298277459 hasConceptScore W4298277459C555293320 @default.
• W4298277459 hasConceptScore W4298277459C61511704 @default.
• W4298277459 hasConceptScore W4298277459C71924100 @default.
• W4298277459 hasLocation W42982774591 @default.
• W4298277459 hasOpenAccess W4298277459 @default.
• W4298277459 hasPrimaryLocation W42982774591 @default.
• W4298277459 hasRelatedWork W142386386 @default.
• W4298277459 hasRelatedWork W1969319209 @default.
• W4298277459 hasRelatedWork W1974770715 @default.
• W4298277459 hasRelatedWork W2003453125 @default.
• W4298277459 hasRelatedWork W2020752782 @default.
• W4298277459 hasRelatedWork W2033096321 @default.
• W4298277459 hasRelatedWork W2142254835 @default.
• W4298277459 hasRelatedWork W2250101314 @default.
• W4298277459 hasRelatedWork W2611563387 @default.
• W4298277459 hasRelatedWork W93237504 @default.
• W4298277459 hasVolume "28 Suppl 3" @default.
• W4298277459 isParatext "false" @default.
• W4298277459 isRetracted "false" @default.
• W4298277459 workType "article" @default.